Technical Analysis for ASNS - Arsanis, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
16.12 | 2.35% | 0.37 |
ASNS closed up 2.35 percent on Wednesday, April 25, 2018, on 44 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| See historical ASNS trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Apr 25 | Wide Bands | Range Expansion | 0.00% |
| Apr 25 | Oversold Stochastic | Weakness | 0.00% |
| Apr 24 | Narrow Range Bar | Range Contraction | 2.35% |
| Apr 24 | Wide Bands | Range Expansion | 2.35% |
| Apr 24 | Oversold Stochastic | Weakness | 2.35% |
| Apr 23 | Narrow Range Bar | Range Contraction | 1.70% |
| Apr 23 | Wide Bands | Range Expansion | 1.70% |
| Apr 23 | Oversold Stochastic | Weakness | 1.70% |
| Apr 20 | Narrow Range Bar | Range Contraction | 3.93% |
| Apr 20 | Lower Bollinger Band Walk | Weakness | 3.93% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-06-08
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
Arsanis, Inc. is a United States-based company engaged in the discovery and development of monoclonal antibodies (mAbs) for the targeted immunotherapy of serious infections. The Company's mAbs focus on specific pathogens and pathogenic processes. Its product pipeline includes ASN100, ASN200, ASN300, ASN400 and ASN500. Its lead program, ASN100, is being studied to prevent hospital-acquired Staphylococcus aureus pneumonia in mechanically ventilated patients heavily colonized with Staphylococcus aureus in their respiratory tracts. Its ASN200 addresses the unmet medical need caused by drug-resistant extra-intestinal escherichia coli infections. Its ASN300 addresses the unmet medical need due to carbapenem-resistant klebsiella pneumoniae infections. Its ASN400 addresses the unmet medical need due to streptococcus pneumoniae, a leading cause of mortality among the elderly. The ASN500 program consisting of potent mAbs targeting respiratory syncytial virus (RSV), is in the discovery phase.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ASNS news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 28.69 |
| 52 Week Low | 10.4 |
| Average Volume | 42,191 |
| 200-Day Moving Average | 0.0 |
| 50-Day Moving Average | 19.054 |
| 20-Day Moving Average | 19.956 |
| 10-Day Moving Average | 16.785 |
| Average True Range | 1.8687 |
| ADX | 25.27 |
| +DI | 17.08 |
| -DI | 26.9 |
| Chandelier Exit (Long, 3 ATRs ) | 20.9739 |
| Chandelier Exit (Short, 3 ATRs ) | 20.8161 |
| Upper Bollinger Band | 27.0422 |
| Lower Bollinger Band | 12.8698 |
| Percent B (%b) | 0.23 |
| BandWidth | 71.01824 |
| MACD Line | -1.4208 |
| MACD Signal Line | -0.7046 |
| MACD Histogram | -0.7162 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.54 | ||||
| Resistance 3 (R3) | 17.43 | 16.85 | 17.30 | ||
| Resistance 2 (R2) | 16.85 | 16.49 | 16.90 | 17.22 | |
| Resistance 1 (R1) | 16.48 | 16.26 | 16.67 | 16.59 | 17.14 |
| Pivot Point | 15.90 | 15.90 | 15.99 | 15.96 | 15.90 |
| Support 1 (S1) | 15.54 | 15.54 | 15.72 | 15.65 | 15.10 |
| Support 2 (S2) | 14.96 | 15.32 | 15.01 | 15.02 | |
| Support 3 (S3) | 14.59 | 14.96 | 14.94 | ||
| Support 4 (S4) | 14.70 |
